RIFALDAZINE

Multiple Sclerosis

SanofiSmall moleculePhase 2Dormant

CCC

55/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 65/ 100

Competitive context

183 Active assets in the Multiple Sclerosis cohort.

Asset / Sponsor	Phase	Rating
Ocrevus Polpharma Biologics International AG	Phase 4	BBB
Nabiximols Jazz Pharmaceuticals	Phase 4	BBB
Cladribine University Hospital, Strasbourg, France	Phase 4	BBB
Teriflunomide Sanofi	Phase 4	BBB
Fampridine MGH Institute of Health Professions	Phase 4	BBB

View all 50 →

Same molecule, other indications

RIFALDAZINE is also rated in:

methicillin-resistant staphylococcus aureus infectious diseaseDormant

BB

Indicative ·

71 / 100

cystic fibrosisDormant

BB

Indicative ·

65 / 100

metabolic dysfunction-associated steatotic liver diseaseDormant

B

Indicative ·

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.